MTOR and hepatocellular carcinoma: Even though the mTOR and Akt inhibitors alone are not potent inhibitors of HCC cell proliferation, they dramatically sensitize the cells to killing by ponatinib, indicating that the activation of PDK1/Akt/mTOR likely enhances the ability of the cells to survive.